| Kent L Adkins, MD | |
|
12855 N 40 Dr, Suite 230, Saint Louis, MO 63141-8657 | |
| (314) 576-3532 | |
| (314) 878-5548 |
| Full Name | Kent L Adkins |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 25 Years |
| Location | 12855 N 40 Dr, Saint Louis, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962460238 | NPI | - | NPPES |
| P00199697 | Other | MO | PALMETTO RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 2003026270 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ssm Depaul Health Center | Bridgeton, MO | Hospital |
| St Luke's Des Peres Hospital | Saint louis, MO | Hospital |
| Mercy Hospital South | Saint louis, MO | Hospital |
| Ssm St Clare Health Center | Fenton, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| American Multispecialty Group Inc | 1658365572 | 151 |
News Archive
GenVec, Inc. announced today that it was awarded a cash grant of approximately $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project program.
An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States.
News outlets noted that as she announced she was leaving the GOP presidential race, Rep. Michele Bachmann continued to criticize the Affordable Care Act
As mammals evolve, so do mammalian viruses. In doing so, they develop creative and effective ways to counter and evade the antiviral responses of their mammal hosts' immune systems.
› Verified 6 days ago
| Entity Name | American Multispecialty Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972559532 PECOS PAC ID: 1658365572 Enrollment ID: O20040413001412 |
News Archive
GenVec, Inc. announced today that it was awarded a cash grant of approximately $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project program.
An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States.
News outlets noted that as she announced she was leaving the GOP presidential race, Rep. Michele Bachmann continued to criticize the Affordable Care Act
As mammals evolve, so do mammalian viruses. In doing so, they develop creative and effective ways to counter and evade the antiviral responses of their mammal hosts' immune systems.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kent L Adkins, MD Po Box 23340, Saint Louis, MO 63156-3340 Ph: (314) 576-3532 | Kent L Adkins, MD 12855 N 40 Dr, Suite 230, Saint Louis, MO 63141-8657 Ph: (314) 576-3532 |
News Archive
GenVec, Inc. announced today that it was awarded a cash grant of approximately $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project program.
An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States.
News outlets noted that as she announced she was leaving the GOP presidential race, Rep. Michele Bachmann continued to criticize the Affordable Care Act
As mammals evolve, so do mammalian viruses. In doing so, they develop creative and effective ways to counter and evade the antiviral responses of their mammal hosts' immune systems.
› Verified 6 days ago
Dr. Charles Phillips Jones, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 4921 Parkview Pl, Div Surg Urology, Ste 11c, Saint Louis, MO 63110 Phone: 314-362-8200 Fax: 314-454-5244 | |
Dr. Carl G Klutke, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1040 N Mason Rd, Ste 122, Saint Louis, MO 63141 Phone: 314-996-8060 Fax: 314-747-4871 | |
Dr. Nitai C Saha, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 533 Couch Ave, Suite 174, Saint Louis, MO 63122 Phone: 314-822-1413 Fax: 314-822-1859 | |
Michael James Glamore, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Dr. James Kelly, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3915 Watson Rd Ste 203, Saint Louis, MO 63109 Phone: 314-771-5822 Fax: 314-771-5827 | |
Maung Htein Thu, M.D Urology Medicare: Accepting Medicare Assignments Practice Location: 12700 Southfork Rd Ste 260, Saint Louis, MO 63128 Phone: 314-543-5270 | |
Dr. Zeynep Gul, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 4921 Parkview Pl, Div Surg Urology, Ste 11c, Saint Louis, MO 63110 Phone: 314-362-8200 Fax: 314-454-5244 |